Physician profile
Sari Stone
NPI 1518693886
$1,511.35
in general payments reported to CMS, 2019-2025
21 companies · $22.62 in 2025
The $22.62 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $117 · 2023: $554 · 2024: $818 · 2025: $22.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,394.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $262.36 | 2023-2024 | |
| Genzyme Corporation | $202.04 | 2024 | |
| Janssen Pharmaceuticals, INC | $116.86 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $87.46 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $87.35 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $80.28 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $75.97 | 2023-2024 | Repatha, Otezla |
| Pfizer INC. | $74.09 | 2023-2024 | |
| Astellas Pharma US INC | $70.44 | 2023-2024 | Veozah |
| Lilly USA, LLC | $66.44 | 2022-2024 | Mounjaro, Zepbound |
| Azurity Pharmaceuticals, INC. | $60.54 | 2023-2024 | Edarbyclor, Edarbyclor |
| Dexcom, INC. | $54.02 | 2023-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $52.26 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.59 | 2022-2023 | Tradjenta, Jardiance |
| Merck Sharp & Dohme LLC | $33.67 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.63 | 2022-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $23.48 | 2022 | |
| Acadia Pharmaceuticals INC | $22.62 | 2025 | Nuplazid |
| Xeris Pharmaceuticals, INC. | $18.26 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $15.40 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sari Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.